Johnson & Johnson JNJ

$261.44 +4.96 (1.93%)

Valuation

Market cap
630,043,712,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
23.62
Forward PE
22.95
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
5,727,200
Avg volume
6,565,684
Day's range
$254.99 – $261.61
Shares out
2,409,898,000
Stochastic %K
50%
Beta
0.21
Analysts
Strong Sell
Price target
$282.76

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

Princeb Oct 12, 4:07 AM
$SLS eneey meeny moniey moe. Who will win the buyout race? $ABBV $MRK $JNJ
1 replies
Techdamentals Oct 12, 3:47 AM
$JNJ reports Tuesday before the open. Its last quarter had sales of $25.3B, up 6.6%, and net earnings of $5.5B, about flat from a year earlier. The Techdamentals IV Calculator reads the reported numbers behind it, with no guru's take. What do its fundamentals actually say? 👇 https://techdamentals.com/v3/JNJ?ref=st Educational, not advice.
0 replies
RyGuy79 Oct 12, 3:01 AM
$SLS Anyone see $JNJ trending on rumors they are looking to buy Sellas? I saw it briefly.
2 replies
thatsolardude365 Oct 12, 2:58 AM
$JNJ: a Baltimore jury returned a roughly $1.5B verdict in a talc case in December; J&J is appealing. No global settlement in the MDL of 68,000 cases; individual lawsuits only, nothing to claim. Open Class Actions.
0 replies
ElliottwaveForecast Oct 12, 1:43 AM
$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 replies
keepingthefaith1 Oct 12, 12:46 AM
$JNJ Buyer usually tanks. Acquired usually rips.
0 replies
Bmann707 Oct 12, 12:37 AM
$CADL just got of the phone with my uncle who works at $JNJ, he said they are buying out this company for 5 billion
5 replies
ms0632 Oct 11, 11:51 PM
$SLS hopefully "this time is different" because I have been following SLS for years now and have never seen a potential "suitor" - $JNJ, TRENDING ahead of SLS on potential acquisition interest. Something might actually be up here for a change, esp with $JNJ ER on Tuesday
1 replies